Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

@article{Janes2010EffectiveAS,
  title={Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor},
  author={Matthew R. Janes and Jose J. Limon and Lomon So and Jing Chen and Raymond Lim and Melissa A Chavez and Collin Vu and Michael B. Lilly and Sharmila Mallya and S. Tiong Ong and Marina Konopleva and Michael B. Martin and Pingda Ren and Yi Liu and Christian Rommel and David A Fruman},
  journal={Nature Medicine},
  year={2010},
  volume={16},
  pages={205-213}
}
Targeting the mammalian target of rapamycin (mTOR) protein is a promising strategy for cancer therapy. The mTOR kinase functions in two complexes, TORC1 (target of rapamycin complex-1) and TORC2 (target of rapamycin complex-2); however, neither of these complexes is fully inhibited by the allosteric inhibitor rapamycin or its analogs. We compared rapamycin with PP242, an inhibitor of the active site of mTOR in both TORC1 and TORC2 (hereafter referred to as TORC1/2), in models of acute leukemia… CONTINUE READING
174 Citations
58 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 174 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 58 references

Foxo and the cycle of life and death

  • Hedrick, S. M. The cunning little vixen
  • Nat. Immunol. 10, 1057–1063
  • 2009

Similar Papers

Loading similar papers…